This morning, Argenica Therapeutics is pleased to announce that the independent Data Safety Monitoring Board (DSMB) has recommended that the Phase 2 clinical trial of ARG-007 in acute ischemic stroke patients continues with no modifications to the study protocol. You can read the full announcement, including our Phase 2 Clinical Trial Update, here ➡️ https://bit.ly/4dSLqEa #ASX #AGN #stroke #strokeawareness #clinicaltrial
Argenica Therapeutics
Pharmaceutical Manufacturing
Nedlands, Perth, Western Australia 1,912 followers
Developing novel neuroprotective therapeutics
About us
Argenica Therapeutics(ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. Moreover, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity. Current treatment options remain limited to restoring blood flow through clot removal by tPA (alteplase) thrombolysis and mechanical thrombectomy. Despite considerable research, there are no marketed drugs capable of protecting the brain from damage following stroke. Therefore, the search for widely applicable and effective neuroprotective drugs for stroke patients remains an urgent unmet need and priority. Argenica has developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy. Specifically, Argenica has developed a neuroprotective therapeutic, ARG-007, that • Slows brain tissue death due to inadequate blood supply • Preserves brain cells and axons • Extends the treatment time window for stroke patients • Is not toxic • Can be delivered in the field by first responders The Company also intends to explore the development and commercialisation of cationic arginine-rich peptides in other neural injury conditions such as perinatal hypoxia, traumatic brain injury, spinal cord injury, and in patients undergoing endovascular procedures that carry a risk of dislodging material from a diseased artery or triggering an embolus to lodge in a brain artery and thereby causing a stroke.
- Website
-
http://www.argenica.com.au
External link for Argenica Therapeutics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Nedlands, Perth, Western Australia
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
Nedlands, Perth, Western Australia 6009, AU
Employees at Argenica Therapeutics
-
Paul Bailey
Medical Coordinator @ WACHS @ Careflight | Emergency Medicine. I provide advice to remote clinicians re complex patient care / logistics needs.…
-
Liddy McCall
Investment Director at Yuuwa
-
Dr Liz Dallimore
CEO & Managing Director at Argenica Therapeutics
-
Emma Waldon
CFO / Company Secretary
Updates
-
If you missed Dr Liz Dallimore providing updates on what's been happening at Argenica Therapeutics in August, you can find all the info through the 'Updates' section of our Investor Hub. Our key media highlights included: ✅ TechKnow Invest Roadshow 2024 ✅ ABC Great Southern Radio with Paul Cook ✅ Sharewise Webinar with Harry Macaskill Catch up on our August media coverage here ➡️ https://bit.ly/4g7x18C #ASX #AGN #investorupdate #strokeawareness
-
-
Did you know you're welcome to ask questions, post comments and leave feedback on our recent announcements through the Argenica Investor Hub? If there is something you would like to know about Argenica Therapeutics, head to ➡️ https://bit.ly/4g8hHbR #ASX #AGN #investorhub #stroke #clinicaltrials
-
-
Recently, Dr Liz Dallimore spoke with Sharewise covering a number of exciting topics relating to our business. If you missed the webinar, you can watch it here ➡️ https://hubs.la/Q02Lw_Rr0 #ARG007 #AGN #ASX #strokeawareness #clinicaltrial
Watch our webinar with Argenica Therapeutics featuring Managing Director Dr Liz Dallimore. The webinar includes an interview and a live Q&A with the audience. Key topics: - Overview of Argenica Therapeutics - Opportunity in stroke - Phase 2 clinical trial - Competitive advantages in the Biotech industry - Key challenges - Team at Argenica - Catalysts and milestones for the next 12-18 months - Long-term outlook for the company Watch here: https://hubs.la/Q02Lw_Rr0 Thank you to Dr Dallimore for joining us.
Argenica Therapeutics (ASX:AGN) | Webinar with Dr. Liz Dallimore | 16/08/24
https://www.youtube.com/
-
Recently, we released our Appendix 4C Quarterly Cashflow Report for the 12-month period ended 30 June 2024. This report highlighted a recent $12M placement completed in the last quarter. Following the placement, Argenica is fully funded to complete its Phase 2 trial of ARG-007 in ischaemic stroke patients, as well as progress studies in its other neurological indications. Read the full report here ➡️ https://bit.ly/4ftygiq #ASX #AGN #investorupdate #stroke #clinicaltrial
-
-
During the last quarter, results were released on a pre-clinical efficacy study which showed ARG-007 significantly reduced damage to brain cells in a ferret animal model of mild to moderate traumatic brain injury (modTBI), a model that closely resembles the gross anatomy of the human brain. Here is a recap of the observed therapeutic effects of ARG-007 in the model. Read the full report ➡️ https://bit.ly/4ftygiq #ASX #AGN #investorupdate #stroke #clinicaltrial
-
-
As a part of National Stroke Week this week, Dr Liz Dallimore spoke with Paul Cook, the host of ABC Great Southern Breakfast about the impact of Stroke in regional communities. According to the Australian Stroke Alliance, only three per cent of patients in rural and remote areas are treated in a stroke unit, compared with 77% of patients in metropolitan areas. And most rural and remote patients need to travel more than 200 kilometres to access care. Together they discuss how ARG-007 could provide “revolutionary change” to the standard of care, particularly in regional areas Listen to the full conversation here ➡️ https://bit.ly/4fxk47Z #ASX #AGN #strokeawareness #regionalWA #regionalcommunities
-
-
Last week, Argenica CEO Dr Liz Dallimore spoke at the TechKnow Invest Roadshow in Sydney and Melbourne. If you were unable to attend, you're now able to watch the Investor Presentation through the link below Watch here ➡️ https://bit.ly/3WR6swN #ASX #AGN #investorpresentation #stroke
-
-
Last week, Argenica Therapeutics lodged our Appendix 4C Quarterly Cashflow Report for the 12-month period ended 30 June 2024. One key highlight from the report was the progress made in our Phase 2 Clinical Trial. Here is an overview of the highlight Access the full report here ➡️ https://bit.ly/4ftygiq #ASX #AGN #investorupdate #stroke #clinicaltrial
-
-
This morning, Argenica Therapeutics lodged our Appendix 4C Quarterly Cashflow Report for the 12-month period ended 30 June 2024. The report highlights the positive progress made in Argenica’s Phase 2 clinical trial. Access the full report here ➡️ https://bit.ly/4ftygiq #ASX #AGN #investorupdate #stroke #clinicaltrial
-